Automated Cell Block System Market Analysis

  • Report ID: 1099
  • Published Date: Sep 29, 2025
  • Report Format: PDF, PPT

Automated Cell Block System Market Segmentation:

Application Segment Analysis

The cancer diagnostics segment is poised to hold the highest share of 65% in the market over the assessed period. Cancer is the leading cause of death and the NLM report in January 2023 depicts that approximately 19.3 million new diagnoses and 10 million deaths are registered globally. As more clinical studies establish the importance of early detection and intervention in cancer care to get a better patient response and minimal financial exhaustion, investments from this segment are magnifying. In this regard, in 2022, a study from the National Cancer Institute highlighted the contribution of ACBS in enhancing accuracy and specificity in precision oncology.

Product Segment Analysis

Instruments and systems lead the market and hold a considerable share in 2035. The segment is dominated to the high capital costs and the transformation towards integrated and high-throughput platforms. As per the CMS report in August 2025, nearly 320,000 clinical laboratories are certified under the Clinical Laboratory Improvement Amendments in the U.S., ensuring high standard in testing quality and accuracy. This creates a recurring revenue model for manufacturers via initial sales of system and long-term service contracts.

End user Segment Analysis

The hospitals & diagnostic labs segment is anticipated to dominate the automated cell block system market throughout the forecasted timeframe. The worldwide trend of modernizing healthcare infrastructure and workflow is a primary driver in the segment's leadership. Additionally, the continuously surging volume of patient admissions and registrations in these organizations garners a greater consumer base and higher revenue for this sector, making it a major distribution channel for global leaders. Moreover, the accumulative investments from government and private companies in hospitals to enhance accessibility ensures a lucrative economic and functional turnaround in this category.

Our in-depth analysis of the global automated cell block system market includes the following segments: 

Segments

Subsegments

Product

 

  • Instruments/Systems
  • Consumables & Reagents (Kits, Reagents, Cassettes)
  • Software & Services

Technology

 

  • Traditional Methods
  • Integrated Workflow Systems
  • Other Advanced Technologies

Application

  • Cancer Diagnostics
    • Traditional Methods
    • Integrated Workflow Systems
    • Other Advanced Technologies
  • Infectious Diseases
    • Traditional Methods
    • Integrated Workflow Systems
    • Other Advanced Technologies
  • Other Diseases
    • Traditional Methods
    • Integrated Workflow Systems
    • Other Advanced Technologies

End user

 

  • Hospitals
    • Cancer Diagnostics
    • Infectious Diseases
    • Other Diseases
  • Diagnostic Laboratories
    • Cancer Diagnostics
    • Infectious Diseases
    • Other Diseases
  • Research Institutes & CROs
    • Cancer Diagnostics
    • Infectious Diseases
    • Other Diseases

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

A size is projected to grow from USD 18.4 billion to USD 45.1 billion, witnessing a CAGR of over 9.4% during the forecast period, between 2026 and 2035.

Automated Cell Block System Market size is set to register remarkable growth rate during the forecast period i.e., between 2026-2035.

North America is anticipated to capture a significant share of 40.5% by 2035 due to ongoing advances in healthcare in the region.

The major players in the market are Danaher Corporation (Cytiva), BD Biosciences, Merck KGaA, Siemens Healthineers, Roche Diagnostics, Tecan Group Ltd.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos